Seres Therapeutics, Inc.
MCRB
NASDAQ·Healthcare·Biotechnology·Mkt cap $55.4M
$5.72
▲ +1.42%
P/E
-2.36
Mkt Cap
$55.4M
52-Wk Range
$4.32–$29.98
52-Week Range
$4.32 - $29.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 75.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary microbiome engineering platform and bacterial consortium technology
- Advanced clinical pipeline with Phase III data for lead candidate SER-109
- Strategic partnerships with Memorial Sloan Kettering Cancer Center and Nestec Ltd.
- First-mover advantage in regulated microbiome therapeutics with multiple disease applications
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Anticipated FDA approval and commercial launch of SER-109 for CDI treatment
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-13.7% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MCRB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.47 vs -$2.18 consensus (+121.6% surprise). Revenue of $736.0K vs $179.0K expected (+311.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+121.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$351.0K
$438.0K
$358.0K
$736.0K
Margins · last 8Q
Gross
100.0%
Profit
622.4%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 23, 2026
vs Industry
How MCRB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.